NCT00620893
Completed
Phase 4
Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK).
ConditionsDry Eye Syndromes
Overview
- Phase
- Phase 4
- Intervention
- PEG- 400 based artificial tear
- Conditions
- Dry Eye Syndromes
- Sponsor
- Bp Consulting, Inc
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- dry eye signs
- Status
- Completed
- Last Updated
- 16 years ago
Overview
Brief Summary
This study will evaluate and compare 2 artificial tears in their ability to reduce post LASIK dry eye signs and symptoms. The secondary endpoint of this study is to evaluate refractive regression in these patients. The 'Refractive Outcome' data point will be defined as the difference between the post-op spherical equivalent (SE) and the pre-op targeted SE.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients ranging from normal to mild dry eye per physician assessment
- •BCVA of 20/20
- •Moderate to high myopia (-3 D to -10D of sphere)
- •Patients who are scheduled to under go myopic bilateral LASIK with VISX laser
Exclusion Criteria
- •Patients currently using topical cyclosporine
- •Patients currently using Systane
- •Patients currently using an oil-based artificial tear such as Soothe or Endura
- •Any post-op epithelial defects or flap complications requiring further procedures (relifting, scraping, stretching etc.)
- •DLK greater than stage 1 or infectious keratitis post-operatively
- •Any uncontrolled systemic disease that may confound the results of this trial (Diabetes, Lupus, Rheumatoid Arthritis etc.)
- •Anisometropia greater than 1D
Arms & Interventions
1
1. PEG-400 based artificial tear
Intervention: PEG- 400 based artificial tear
2
2. Systane
Intervention: Systane
Outcomes
Primary Outcomes
dry eye signs
Time Frame: 9 months
Secondary Outcomes
- refractive regression(9 months)
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 4
Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual QualityDry EyeNCT00622037Bp Consulting, Inc70
Completed
Phase 4
Efficacy of PEG-400 and Systane Artificial Tears (Alcon) on Quality of VisionMyopiaNCT00627302Bp Consulting, Inc40
Completed
Phase 4
Evaluate Artificial Tear Efficacy in Moderate to Severe Dry EyeDry EyeNCT00724412Alcon Research279
Completed
Phase 4
Masked Comparison of a New PEG Based Artificial Tear and Optive for Comfort, Vision & Wear Time in Patients Wearing Contact LensesComfort, Vision and Wear TimeNCT00570843Bp Consulting, Inc50
Unknown
Not Applicable
Comparison of the Clinical Effects of Two Tear Substitutes in Patients With Dry Eye SyndromeDry EyeNCT02992392Sun Yat-sen University50